Etoricoxib

Generic Name: Etoricoxib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₁₅ClN_₂O_₂S

CAS Number: 202409-33-4

Unique Ingredient Identifier: WRX4NFY03R

Background: Etoricoxib is a new COX-2 selective inhibitor. Current therapeutic indications are: treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout. Like any other COX-2 selective inhibitor, Etoricoxib selectively inhibits isoform 2 of cyclo-oxigenase enzyme (COX-2) to reduce the generation of prostaglandins (PGs) from arachidonic acid. It is approved in more than 60 countries worldwide but not in the US.

Indication: For the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout.

Associated Conditions: Ankylosing Spondylitis (AS), Gout, Osteoarthritis (OA), Rheumatoid Arthritis, Moderate Pain

Associated Therapies: -

Clinical Trials

Preemptive Analgesia in Cruciate Reconstruction

Phase 3

Completed

Conditions: Anterior Cruciate Ligament Injury

Interventions: Drug: Celecoxib
Drug: etoricoxib

First Posted Date: 2009-11-20

Last Posted Date: 2009-11-20

Lead Sponsor: Prince of Songkla University

Target Recruit Count: 30

Registration Number: NCT01017380

Locations: 🇹🇭
Prince of Songkla University, Hat Yai, Songkhla, Thailand

COX-2 Inhibition in Allergic Asthma

Not Applicable

Completed

Conditions: Asthma

Interventions: Drug: Etoricoxib

First Posted Date: 2009-10-27

Last Posted Date: 2013-04-24

Lead Sponsor: Barbro Dahlen

Target Recruit Count: 16

Registration Number: NCT01002690

Locations: 🇸🇪
Karolinska University Hospital, Stockholm, Sweden

Study of the Bioequivalence of the 20% and 30% Etoricoxib Tablet Formulations (0663-070)

Phase 1

Completed

Conditions: Pain

Interventions: Drug: etoricoxib

First Posted Date: 2009-07-23

Last Posted Date: 2022-02-09

Lead Sponsor: Organon and Co

Target Recruit Count: 36

Registration Number: NCT00945035

Etoricoxib for Postoperative Pain After Thyroid Surgery

Phase 4

Conditions: Acute Pain

Interventions: Drug: etoricoxib

First Posted Date: 2009-07-08

Last Posted Date: 2009-07-08

Lead Sponsor: Hospital Padre Hurtado

Target Recruit Count: 70

Registration Number: NCT00935116

Etoricoxib Versus Ibuprofen in Third Molar Extraction Pain

Phase 4

Conditions: Dental Extraction

Interventions: Drug: etoricoxib
Drug: ibuprofen

First Posted Date: 2009-03-04

Last Posted Date: 2009-03-04

Lead Sponsor: Universita di Verona

Target Recruit Count: 110

Registration Number: NCT00855777

"NSAIDs in Acute Achilles Tendinopathy: Effect on Pain Control, Leg Stiffness and Functional Recovery in Athletes"

Phase 4

Completed

Conditions: Achilles Tendinopathy

Interventions: Drug: etoricoxib
Drug: diclofenac

First Posted Date: 2008-11-17

Last Posted Date: 2013-08-06

Lead Sponsor: Argentine Tennis Association

Target Recruit Count: 56

Registration Number: NCT00792376

Locations: 🇦🇷
Argentine Tennis Association, Buenos Aires, Argentina

Study to Evaluate the Efficacy of Pre-operative Administration of Etoricoxib 120 mg, Etoricoxib 120 mg and Paracetamol 1 g Combination or Placebo in the Treatment of Postoperative Pain in Patients Undergoing Gynaecologic Laparoscopic Surgery

Phase 4

Terminated

Conditions: Pain

Interventions: Drug: etoricoxib

First Posted Date: 2008-10-01

Last Posted Date: 2012-01-31

Lead Sponsor: East Tallinn Central Hospital

Target Recruit Count: 40

Registration Number: NCT00763685

Locations: 🇪🇪
East Tallinn Central Hospital, Tallinn, Estonia

Patient-Reported Effectiveness and Safety of Etoricoxib in Osteoarthritis (OA)(0663-113)

Phase 4

Completed

Conditions: Pain

Interventions: Drug: etoricoxib

First Posted Date: 2008-09-23

Last Posted Date: 2022-02-09

Lead Sponsor: Organon and Co

Target Recruit Count: 500

Registration Number: NCT00757627

Study Assessing the Efficacy of Etoricoxib in Female Patients With Fibromyalgia

Phase 4

Conditions: Fibromyalgia

Interventions: Drug: etoricoxib

First Posted Date: 2008-09-19

Last Posted Date: 2012-08-10

Lead Sponsor: Meir Medical Center

Target Recruit Count: 80

Registration Number: NCT00755521

Locations: 🇮🇱
Department of Medicine 'D', Meir Medical Center, Kfar-Saba, Israel

Randomized Placebo Controlled Trial With Etoricoxib That is Taken to Prevent the Yom Kippur Headache

Phase 4

Conditions: Headache

Interventions: Drug: placebo
Drug: etoricoxib

First Posted Date: 2008-09-16

Last Posted Date: 2008-09-16

Lead Sponsor: Shaare Zedek Medical Center

Target Recruit Count: 200

Registration Number: NCT00752921

Locations: 🇮🇱
Shaare Zedek Medical Center, Jerusalem, Israel

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy